Cholesterol Numbers Explained: ApoB, LDL and What to Act On

Most people get a cholesterol test, glance at the numbers, and move on. The problem is that the standard lipid panel tells only part of the story, and sometimes the most important part is missing entirely. Understanding what your cholesterol numbers actually mean, and which ones deserve your attention, can be the difference between catching cardiovascular risk early and missing it altogether.

What a Standard Lipid Panel Actually Measures

When your doctor orders a "cholesterol test," you typically receive four numbers:

• Total cholesterol - the sum of all cholesterol carried in your blood
• LDL-C (low-density lipoprotein cholesterol) - often called "bad" cholesterol
• HDL-C (high-density lipoprotein cholesterol) - often called "good" cholesterol
• Triglycerides - a type of fat that circulates in your blood after meals

These values are reported in millimoles per litre (mmol/L) in most European labs. LDL-C has historically been the primary target for treatment decisions, and for good reason: decades of evidence confirm that lowering LDL-C reduces heart attacks and strokes.

But LDL-C is a measure of the cholesterol content inside LDL particles. It does not tell you how many particles are actually circulating, and that distinction matters more than most people realise.

Why LDL-C Can Be Misleading

Imagine two people with the same LDL-C of 3.0 mmol/L. Person A has a moderate number of large, cholesterol-rich LDL particles. Person B has a high number of smaller particles, each carrying less cholesterol but adding up to the same total.

Person B has more particles penetrating the arterial wall, which means more opportunities for plaque to develop, yet their LDL-C looks identical on paper.

This scenario is especially common in people with metabolic syndrome, insulin resistance, type 2 diabetes, or elevated triglycerides. In these groups, LDL-C can appear "normal" while the actual atherogenic particle count is dangerously high. This is sometimes called discordance, and it is one of the most important blind spots in routine screening.

Enter ApoB: A Better Count of Dangerous Particles

Apolipoprotein B, or ApoB, is a protein found on the surface of every atherogenic lipoprotein particle. Each LDL particle carries exactly one ApoB molecule. So do VLDL particles, intermediate-density lipoproteins (IDL), and lipoprotein(a) particles.

Measuring ApoB gives you a direct count of all the particles capable of driving atherosclerosis, not just LDL. This makes it a more comprehensive and often more accurate marker of cardiovascular risk than LDL-C alone.

Key advantages of ApoB:

• It captures risk from particles that LDL-C misses, including VLDL remnants
• It remains accurate in people with high triglycerides, where standard LDL-C calculations become unreliable
• It resolves discordance, identifying high-risk individuals whose LDL-C appears reassuring
• Major European cardiovascular guidelines now recognise ApoB as a valuable, and in some contexts superior, risk marker

A general target for ApoB in the European guidelines is below 1.0 g/L for the general population, with lower targets (below 0.65 g/L or even 0.55 g/L) for people at high or very high cardiovascular risk.

What About HDL and Triglycerides?

HDL-C was long considered "protective" cholesterol, and higher levels were seen as universally beneficial. The picture is more nuanced than that. While low HDL-C does correlate with higher cardiovascular risk, trials that artificially raised HDL-C with medication failed to reduce events. HDL likely matters, but the number on your lab report is not a reliable treatment target.

Triglycerides, on the other hand, have gained renewed attention. Elevated triglycerides (above 1.7 mmol/L) are a marker of metabolic dysfunction and are associated with an increased number of atherogenic remnant particles. Persistently high triglycerides often signal insulin resistance and warrant a closer look at diet, body composition, and metabolic health.

When triglycerides are elevated, standard LDL-C calculations (using the Friedewald equation) become less accurate. This is another situation where ApoB or directly measured LDL-C provides a clearer picture.

Lipoprotein(a): The Inherited Risk Factor You Should Know About

Lipoprotein(a), written as Lp(a), is a genetically determined lipoprotein particle that increases cardiovascular and aortic valve disease risk. Your Lp(a) level is largely set by your genes and does not change much with diet or standard medications.

About 20% of the population has elevated Lp(a). Because levels are stable over a lifetime, it only needs to be measured once. If elevated, it changes how aggressively other risk factors, particularly LDL-C and ApoB, should be managed.

Lp(a) is not included in routine lipid panels, so you may need to specifically request it. Therapies targeting Lp(a) directly are in advanced clinical development, but for now, knowing your level helps calibrate your overall risk profile.

When Should You Act on Your Numbers?

Not every abnormal cholesterol number requires medication. Treatment decisions depend on your overall cardiovascular risk, which accounts for age, blood pressure, smoking status, diabetes, family history, and lipid levels together.

However, certain situations call for prompt attention:

• LDL-C above 5.0 mmol/L or ApoB above 1.3 g/L, which may suggest familial hypercholesterolaemia
• A strong family history of premature heart disease (heart attack or stroke before age 55 in men or 65 in women)
• Known cardiovascular disease, where aggressive lipid lowering is well established to reduce recurrent events
• Persistent discordance between LDL-C and ApoB, especially in the context of metabolic syndrome or diabetes

Lifestyle remains the foundation: regular physical activity, a diet rich in whole foods and fibre, maintaining a healthy weight, and not smoking all meaningfully improve lipid profiles and reduce risk. When lifestyle is not enough, statins remain the first-line pharmacological treatment, with additional options available for people who need further lowering.

How Telehealth Fits Into Lipid Management

Monitoring cholesterol does not always require an in-person visit. Once bloodwork is complete, interpreting results, adjusting treatment plans, and following up on lifestyle changes can often be handled through a telehealth consultation. This is particularly useful for routine lipid reviews, medication titration, and ongoing risk assessment.

Telehealth complements, rather than replaces, in-person care. If imaging, physical examination, or specialist referral is needed, your clinician will guide you accordingly. But for the many people who simply need their numbers reviewed and a clear plan of action, a virtual consultation removes unnecessary barriers.

What to Ask at Your Next Review

Armed with this knowledge, consider raising these questions with your doctor:

• Has my ApoB been measured, and if not, should it be?
• Is there discordance between my LDL-C and ApoB?
• Should I have a one-time Lp(a) measurement?
• What is my overall cardiovascular risk, not just my cholesterol number?
• Are my triglycerides signalling a metabolic issue worth investigating?

Cholesterol management has moved well beyond a single LDL-C target. The more precisely you understand your lipid profile, the more effectively you and your doctor can act on it.

---

This article is for informational purposes only and does not constitute personalised medical advice. Cholesterol targets and treatment decisions should be made in consultation with a licensed physician who can assess your individual risk profile. If you have questions about your lipid results, consider booking a consultation with an AETHERA Health clinician.